Home/Filings/4/0001104659-19-053617
4//SEC Filing

5AM Ventures IV, L.P. 4

Accession 0001104659-19-053617

CIK 0001781983other

Filed

Oct 8, 8:00 PM ET

Accepted

Oct 9, 6:23 PM ET

Size

34.3 KB

Accession

0001104659-19-053617

Insider Transaction Report

Form 4
Period: 2019-10-07
Transactions
  • Conversion

    Common Stock

    2019-10-07+79,74680,253 total(indirect: See footnotes)
  • Conversion

    Series C Convertible Preferred Stock

    2019-10-0720,5190 total(indirect: See footnotes)
    Common Stock (20,519 underlying)
  • Conversion

    Common Stock

    2019-10-07+20,519100,772 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-071,913,9100 total(indirect: See footnotes)
    Common Stock (1,913,910 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-10-07492,4750 total(indirect: See footnotes)
    Common Stock (492,475 underlying)
  • Conversion

    Common Stock

    2019-10-07+1,913,9101,926,073 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2019-10-07+492,4752,418,548 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2019-10-07$15.00/sh+333,333$4,999,995333,333 total(indirect: See footnotes)
  • Conversion

    Series B Convertible Preferred Stock

    2019-10-0779,7460 total(indirect: See footnotes)
    Common Stock (79,746 underlying)
Footnotes (6)
  • [F1]These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
  • [F2]Shares are held directly by 5AM Ventures IV, L.P.
  • [F3]Shares are held directly by 5AM Co-Investors IV, L.P.
  • [F4]5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.
  • [F5]Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.
  • [F6]5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Mr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.

Documents

1 file

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001589315

Filing Metadata

Form type
4
Filed
Oct 8, 8:00 PM ET
Accepted
Oct 9, 6:23 PM ET
Size
34.3 KB